121 related articles for article (PubMed ID: 2679850)
1. c-myc oncogene product expression and prognosis in operable breast cancer.
Locker AP; Dowle CS; Ellis IO; Elston CW; Blamey RW; Sikora K; Evan G; Robins RA
Br J Cancer; 1989 Nov; 60(5):669-72. PubMed ID: 2679850
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical studies on oncogene products (c-erbB-2, EGFR, c-myc) and estrogen receptor in benign and malignant breast lesions. With special reference to their prognostic significance in carcinoma.
Tauchi K; Hori S; Itoh H; Osamura RY; Tokuda Y; Tajima T
Virchows Arch A Pathol Anat Histopathol; 1989; 416(1):65-73. PubMed ID: 2573192
[TBL] [Abstract][Full Text] [Related]
3. High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique.
Spandidos DA; Field JK; Agnantis NJ; Evan GI; Moore JP
Anticancer Res; 1989; 9(4):821-6. PubMed ID: 2683996
[TBL] [Abstract][Full Text] [Related]
4. ras, c-myc and c-erbB-2 oncoproteins in human breast cancer.
Spandidos DA; Yiagnisis M; Papadimitriou K; Field JK
Anticancer Res; 1989; 9(5):1385-93. PubMed ID: 2574023
[TBL] [Abstract][Full Text] [Related]
5. Oncogene protein co-expression. Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma.
Bland KI; Konstadoulakis MM; Vezeridis MP; Wanebo HJ
Ann Surg; 1995 Jun; 221(6):706-18; discussion 718-20. PubMed ID: 7794075
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of c-erbB-2 and estrogen receptor status in human breast cancer.
McCann AH; Dervan PA; O'Regan M; Codd MB; Gullick WJ; Tobin BM; Carney DN
Cancer Res; 1991 Jun; 51(12):3296-303. PubMed ID: 1674898
[TBL] [Abstract][Full Text] [Related]
7. int-2 amplification in breast cancer: association with decreased survival and relationship to amplification of c-erbB-2 and c-myc.
Henry JA; Hennessy C; Levett DL; Lennard TW; Westley BR; May FE
Int J Cancer; 1993 Mar; 53(5):774-80. PubMed ID: 8449602
[TBL] [Abstract][Full Text] [Related]
8. c-erbB-2/c-erbA co-amplification indicative of lymph node metastasis, and c-myc amplification of high tumour grade, in human breast carcinoma.
Tavassoli M; Quirke P; Farzaneh F; Lock NJ; Mayne LV; Kirkham N
Br J Cancer; 1989 Oct; 60(4):505-10. PubMed ID: 2572268
[TBL] [Abstract][Full Text] [Related]
9. Comparison of deoxyribonucleic acid ploidy and nuclear expressed p62 c-myc oncogene in the prognosis of colorectal cancer.
Rowley S; Newbold KM; Gearty J; Keighley MR; Donovan IA; Neoptolemos JP
World J Surg; 1990; 14(4):545-50; discussion 551. PubMed ID: 2200214
[TBL] [Abstract][Full Text] [Related]
10. Strong association between c-myb and oestrogen-receptor expression in human breast cancer.
Guérin M; Sheng ZM; Andrieu N; Riou G
Oncogene; 1990 Jan; 5(1):131-5. PubMed ID: 2181374
[TBL] [Abstract][Full Text] [Related]
11. c-erbB-2 oncoprotein expression in primary and advanced breast cancer.
Lovekin C; Ellis IO; Locker A; Robertson JF; Bell J; Nicholson R; Gullick WJ; Elston CW; Blamey RW
Br J Cancer; 1991 Mar; 63(3):439-43. PubMed ID: 1672254
[TBL] [Abstract][Full Text] [Related]
12. Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival.
Pietiläinen T; Lipponen P; Aaltomaa S; Eskelinen M; Kosma VM; Syrjänen K
Anticancer Res; 1995; 15(3):959-64. PubMed ID: 7645986
[TBL] [Abstract][Full Text] [Related]
13. Correlation between c-erbB-2 amplification and risk of recurrent disease in node-negative breast cancer.
Paterson MC; Dietrich KD; Danyluk J; Paterson AH; Lees AW; Jamil N; Hanson J; Jenkins H; Krause BE; McBlain WA
Cancer Res; 1991 Jan; 51(2):556-67. PubMed ID: 1670762
[TBL] [Abstract][Full Text] [Related]
14. Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer.
Yasojima H; Shimomura A; Naoi Y; Kishi K; Baba Y; Shimazu K; Nakayama T; Kim SJ; Tamaki Y; Noguchi S
Eur J Cancer; 2011 Aug; 47(12):1779-88. PubMed ID: 21741827
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-erbB-2 oncoprotein: a prognostic indicator in human breast cancer.
Wright C; Angus B; Nicholson S; Sainsbury JR; Cairns J; Gullick WJ; Kelly P; Harris AL; Horne CH
Cancer Res; 1989 Apr; 49(8):2087-90. PubMed ID: 2564806
[TBL] [Abstract][Full Text] [Related]
16. Amplification of the proto-oncogenes int-2, c-erb B-2 and c-myc in human breast cancer.
Machotka SV; Garrett CT; Schwartz AM; Callahan R
Clin Chim Acta; 1989 Oct; 184(3):207-17. PubMed ID: 2611995
[TBL] [Abstract][Full Text] [Related]
17. Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia.
Hendy-Ibbs P; Cox H; Evan GI; Watson JV
Br J Cancer; 1987 Mar; 55(3):275-82. PubMed ID: 3552016
[TBL] [Abstract][Full Text] [Related]
18. Use of the OM-11-906 monoclonal antibody for determining p62 c-myc expression by flow cytometry in relation to prognosis in colorectal cancer.
Rowley S; Carpenter R; Newbold KM; Gearty J; Keighley MR; Donovan IA; Neoptolemos JP
Eur J Surg Oncol; 1991 Aug; 17(4):370-8. PubMed ID: 1874294
[TBL] [Abstract][Full Text] [Related]
19. Comparative long-term prognostic value of quantitative HER-2/neu protein expression, DNA ploidy, and morphometric and clinical features in paraffin-embedded invasive breast cancer.
Baak JP; Chin D; van Diest PJ; Ortiz R; Matze-Cok P; Bacus SS
Lab Invest; 1991 Feb; 64(2):215-23. PubMed ID: 1671789
[TBL] [Abstract][Full Text] [Related]
20. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers.
Park K; Kwak K; Kim J; Lim S; Han S
Hum Pathol; 2005 Jun; 36(6):634-9. PubMed ID: 16021569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
